This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Prognostic Value of Noninvasive Cardiovascular Testing in Patients with Stable Chest Pain
Share |

Prognostic Value of Noninvasive Cardiovascular Testing in Patients with Stable Chest Pain: Insights from the PROMISE Trial

 

This recent paper in Circulation, Prognostic Value of Noninvasive Cardiovascular Testing in Patients w/ Stable Chest Pain: Insights from PROMISE Trial, highlights  results from PROMISE trial. The paper demonstrates that coronary CTA, by identifying patients at risk due to nonobstructive CAD, provides better prognostic information than functional testing in contemporary stable chest pain patients with a low burden of obstructive CAD, myocardial ischemia, and events.

"Our work provides generalizable data for one of the fundamental elements of cardiology patient care establishing that hallmarks of traditional stable chest pain assessment such as obstructive CAD and myocardial ischemia have comparable prognostic value'" says lead author Udo Hoffmann, MD. "However, as other studies have shown, statins and improved cardiovascular risk management have lowered the clinical event risk of these patients as compared to 30 years ago. In this changed situation, we clearly show the benefit of CTA being able to detect subclinical atherosclerotic disease, i.e. non-obstructive CAD to identify an additional at risk population, in which a large proportion of future clinical events occur. I believe these data will enable caregivers to make an objective data driven choice as to which diagnostic test may be most beneficial for a patient presenting with stable chest pain."

 

Authors: Udo Hoffmann, Maros Ferencik, James E. Udelson, Michael H. Picard, Quynh A. Truong, Manesh R. Patel, Megan Huang, Michael J. Pencina, Daniel B. Mark, John F. Heitner, Christopher B. Fordyce, Patricia A. Pellikka, Jean-Claude Tardif, Matthew J. Budoff, George Nahhas, Benjamin J. Chow, Andrzej S. Kosinski, Kerry L. Lee, Pamela S. Douglas
and on behalf of the PROMISE Investigators

DOI:  https://doi.org/10.1161/CIRCULATIONAHA.116.024360
Circulation. 2017;CIRCULATIONAHA.116.024360
Originally published April 7, 2017

 

703-766-1706
800-876-4195

415 Church St. NE, Suite 204
Vienna, VA 22180-4751